Researchers at Korea’s KRICT identified a novel SRV2 envelope protein intended to improve viral vector efficiency for producing CAR immune cells. The group said the approach targets manufacturing throughput and yield challenges that affect scaling of next-generation cell and gene therapies. The disclosure positions the envelope protein work as an enabling technology for CAR platforms, where vector performance can translate into more consistent downstream cell manufacturing. For cell therapy developers, improvements in vector efficiency can reduce cost and variability across batches. This is part of a broader wave of vector-engineering efforts aimed at de-risking commercialization for CAR immune cell therapies.